WBX +44.2% Leads EPS Revision Surge; BBIO, HOOD, NET, BCRX Also Rally
Five stocks detected by our EPS revision screener have delivered double-digit gains since June 30. WBX soared 44.2% after a 10.6pp EPS growth revision and a $15.8M equity raise. BBIO gained 21.2% on a $1B preferred equity investment, while HOOD, NET, and BCRX posted returns of 14.9%, 11.1%, and 10.9% respectively on upward estimate revisions and supportive catalysts.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| WBX | Technology | 2026-06-30 | +10.6pp | +44.2% |
| BBIO | Healthcare | 2026-06-30 | N/A | +21.2% |
| HOOD | Financial | 2026-06-30 | N/A | +14.9% |
| NET | Technology | 2026-07-06 | N/A | +11.1% |
| BCRX | Healthcare | 2026-06-30 | +5.9pp | +10.9% |
Why did WBX stock jump in July 2026?
WBX jumped 44.2% (from $3.82 to $5.51) after analysts raised its forward EPS growth estimate from 50.6% to 61.3% on June 30.
The revision was reinforced by a $15.8M equity raise on July 2 and the announcement of Q2 2026 earnings results timing on July 7. Together, these catalysts signaled strengthening fundamentals and improved liquidity, driving the surge.
WBX EPS revision history → · Screener snapshot from 2026-06-30 →
Why did BBIO stock jump in July 2026?
BBIO jumped 21.2% (from $74.48 to $90.25) after analysts raised its forward EPS growth estimate to 124.9% on June 30.
The upward revision was validated by a $1B preferred equity investment led by Sixth Street and HealthCare Royalty/KKR on July 1, which accelerates launches of Attruby and three other potential blockbusters. The price gain reflects the market's confidence in the company's expanded runway and commercial momentum.
BBIO EPS revision history → · Screener snapshot from 2026-06-30 →
Why did HOOD stock jump in July 2026?
HOOD jumped 14.9% (from $100.28 to $115.26) after analysts raised its forward EPS growth estimate to 38.6% on June 30.
Despite a broad tech sell-off and new competition from Gemini's zero-commission stock trading, the EPS revision attracted buyers. Analyst commentary highlighting Robinhood's 'generational' opportunity and retail relationship moat supported the move.
HOOD EPS revision history → · Screener snapshot from 2026-06-30 →
Why did NET stock jump in July 2026?
NET jumped 11.1% (from $247.55 to $274.98) after analysts raised its forward EPS growth estimate to 32.2% on July 6.
The revision was immediately followed by a Scotiabank upgrade to Outperform with a $300 price target, citing Cloudflare's AI-native customer wins and its Workers platform as underappreciated drivers. The upgrade provided a clear catalyst within two days of detection.
NET EPS revision history → · Screener snapshot from 2026-07-06 →
Why did BCRX stock jump in July 2026?
BCRX jumped 10.9% (from $10.00 to $11.09) after analysts raised its forward EPS growth estimate from 111.7% to 117.6% on June 30.
No company-specific news followed, but the nearly 6pp revision alone signaled accelerating earnings momentum. The gain likely benefited from broader healthcare sector tailwinds and momentum-driven buying.
BCRX EPS revision history → · Screener snapshot from 2026-06-30 →
Today's performers show that upward EPS revisions remain a reliable early indicator of price appreciation, especially when amplified by capital raises, analyst upgrades, or commercial catalysts. The breadth of gains across tech and healthcare suggests the market is rewarding fundamental improvement over macro uncertainty.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →